Short Interest Worth Watching: What’s in Alkermes Plc Ord (NASDAQ:ALKS) After Rise in Shorted Shares?

November 24, 2016 - By Dolores Ford   ·   0 Comments

Short Interest Worth Watching: What’s in Alkermes Plc Ord (NASDAQ:ALKS) After Rise in Shorted Shares?

The stock of Alkermes Plc Ord (NASDAQ:ALKS) registered an increase of 27.86% in short interest. ALKS’s total short interest was 5.54M shares in November as published by FINRA. Its up 27.86% from 4.33 million shares, reported previously. With 2.57M shares average volume, it will take short sellers 2 days to cover their ALKS’s short positions. The short interest to Alkermes Plc Ord’s float is 4.31%. The stock increased 1.13% or $0.66 on November 23, hitting $59. About 602,973 shares traded hands. Alkermes Plc (NASDAQ:ALKS) has risen 38.27% since April 22, 2016 and is uptrending. It has outperformed by 32.86% the S&P500.

Alkermes Public Limited Company is a biopharmaceutical company. The company has a market cap of $8.84 billion. The Firm is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It currently has negative earnings. The Firm has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system disorders, such as schizophrenia, depression, addiction and multiple sclerosis.

Insitutional Activity: The institutional sentiment increased to 1.2 in Q2 2016. Its up 0.24, from 0.96 in 2016Q1. The ratio increased, as 31 funds sold all Alkermes Plc shares owned while 75 reduced positions. 34 funds bought stakes while 68 increased positions. They now own 135.77 million shares or 0.84% less from 136.92 million shares in 2016Q1.
Aviva Public Ltd Com has 0.02% invested in the company for 79,401 shares. Cibc Asset Mgmt, a Ontario – Canada-based fund reported 6,300 shares. Dai Ichi Life Insur has invested 0.04% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Financial Bank Of Montreal Can holds 0.01% or 102,082 shares in its portfolio. Moreover, Signaturefd Ltd Llc has 0% invested in Alkermes Plc (NASDAQ:ALKS) for 35 shares. Tfs Capital Ltd Liability Co holds 0.07% of its portfolio in Alkermes Plc (NASDAQ:ALKS) for 8,748 shares. Brc Inv Limited Liability Company holds 0.12% or 16,036 shares in its portfolio. Moreover, Evercore Wealth Mngmt Ltd Com has 0.03% invested in Alkermes Plc (NASDAQ:ALKS) for 14,200 shares. Tocqueville Asset Mgmt Limited Partnership owns 726,065 shares or 0.4% of their US portfolio. Van Eck Associate last reported 213,985 shares in the company. The California-based California Pub Employees Retirement System has invested 0.02% in Alkermes Plc (NASDAQ:ALKS). Bb&T Corp accumulated 10,199 shares or 0.01% of the stock. Td Cap Management Ltd Liability last reported 20 shares in the company. Quantbot Tech Lp has invested 0% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Meditor Grp Incorporated Limited accumulated 18.13% or 1.03M shares.

Alkermes Plc (NASDAQ:ALKS) Ratings Coverage

Out of 8 analysts covering Alkermes (NASDAQ:ALKS), 6 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 75% are positive. Alkermes has been the topic of 16 analyst reports since September 1, 2015 according to StockzIntelligence Inc. The stock of Alkermes Plc (NASDAQ:ALKS) earned “Overweight” rating by Barclays Capital on Wednesday, October 7. Morgan Stanley upgraded it to “Overweight” rating and $85 target price in Tuesday, September 1 report. Leerink Swann maintained it with “Outperform” rating and $58 target price in Thursday, January 21 report. JP Morgan downgraded the shares of ALKS in a report on Thursday, January 21 to “Neutral” rating. The stock of Alkermes Plc (NASDAQ:ALKS) has “Overweight” rating given on Friday, July 29 by Barclays Capital. Jefferies maintained Alkermes Plc (NASDAQ:ALKS) rating on Friday, October 21. Jefferies has “Buy” rating and $70 price target. The stock of Alkermes Plc (NASDAQ:ALKS) earned “Buy” rating by Evercore on Thursday, May 26. The firm has “Outperform” rating given on Friday, October 21 by Leerink Swann. The firm has “Market Perform” rating by Cowen & Co given on Tuesday, July 26. The stock of Alkermes Plc (NASDAQ:ALKS) has “Overweight” rating given on Friday, October 21 by JP Morgan.

ALKS Company Profile

Alkermes Public Limited Company, incorporated on May 4, 2011, is a biopharmaceutical company. The Firm is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Firm has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. The Company’s products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. The Company’s product platforms include injectable extended release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.

More recent Alkermes Plc (NASDAQ:ALKS) news were published by: Fool.com which released: “Why Alkermes PLC Skyrocketed Today” on October 21, 2016. Also Fool.com published the news titled: “Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward” on November 07, 2016. Businesswire.com‘s news article titled: “Alkermes plc Reports Third Quarter 2016 Financial Results” with publication date: November 02, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>